Literature DB >> 20224729

Development of acute lympboblastic leukemia in a patient with increased hematogones after toxic bone marrow damage.

Stefan Gattenlöhner1, Hermann Einsele.   

Abstract

To the best of our knowledge we describe the first case showing the association of increased B cell precursors/hematogones in a regenerating post-toxic bone marrow with subsequent development of a B-ALL. Since all immunohistochemical/moleculargenetic anaylses have failed to identify the initial malignant leukemic clone, we suggest a close-meshed follow-up of such cases to identify potential mechanisms for the malignant transformation of B-cell precursors/hematogones and to prevent further fatal courses.

Entities:  

Keywords:  B-ALL; Bone marrow; hematogones; toxic damage

Mesh:

Substances:

Year:  2010        PMID: 20224729      PMCID: PMC2836508     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  4 in total

1.  Distinct expression patterns of CD123 and CD34 on normal bone marrow B-cell precursors ("hematogones") and B lymphoblastic leukemia blasts.

Authors:  Nagwa M Hassanein; Felisa Alcancia; Kathryn R Perkinson; Patrick J Buckley; Anand S Lagoo
Journal:  Am J Clin Pathol       Date:  2009-10       Impact factor: 2.493

Review 2.  Involvement of SLP-65 and Btk in tumor suppression and malignant transformation of pre-B cells.

Authors:  Rudi W Hendriks; Rogier Kersseboom
Journal:  Semin Immunol       Date:  2005-11-21       Impact factor: 11.130

3.  Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features.

Authors:  L M Rimsza; R S Larson; S S Winter; K Foucar; Y Y Chong; K W Garner; C P Leith
Journal:  Am J Clin Pathol       Date:  2000-07       Impact factor: 2.493

Review 4.  Molecular genetics of acute lymphoblastic leukemia.

Authors:  Michael A Teitell; Pier Paolo Pandolfi
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.